Skip to main content

Peer Review reports

From: Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

Original Submission
8 Aug 2013 Submitted Original manuscript
1 Mar 2014 Reviewed Reviewer Report - Mark Danese
24 Mar 2014 Reviewed Reviewer Report - Sarah Dewilde
Resubmission - Version 2
Submitted Manuscript version 2
20 May 2014 Author responded Author comments - Sara Khor
Resubmission - Version 3
20 May 2014 Submitted Manuscript version 3
13 Jun 2014 Reviewed Reviewer Report - Mark Danese
16 Jun 2014 Reviewed Reviewer Report - Sarah Dewilde
26 Jun 2014 Author responded Author comments - Sara Khor
Resubmission - Version 4
26 Jun 2014 Submitted Manuscript version 4
18 Jul 2014 Author responded Author comments - Sara Khor
Resubmission - Version 5
18 Jul 2014 Submitted Manuscript version 5
Publishing
31 Jul 2014 Editorially accepted
12 Aug 2014 Article published 10.1186/1471-2407-14-586

You can find further information about peer review here.

Back to article page